Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 701–800 of 1,001
HER2-Positive Breast Cancer Treatment and Resistance
Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 26
A novel approach for next‐generation sequencing of circulating tumor cells
Yee, S. S., Lieberman, D. B., Blanchard, T., Rader, J., Zhao, J., Troxel, A. B., DeSloover, D., Fox, A. J., Daber, R. D., Kakrecha, B., et al. (2016) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.210 · Cited by 24
Kiesewetter, B., Raderer, M., Steger, G. G., Bartsch, R., Pirker, R., Zöchbauer‐Müller, S., Prager, G. W., Krainer, M., Preusser, M., Schmidinger, M., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000066 · Cited by 23
Li, L., & Pan, Z. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.07.015 · Cited by 21
Update Breast Cancer 2017 – Implementation of Novel Therapies
Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., Ettl, J., et al. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-122885 · Cited by 22
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9925 · Cited by 21
Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer
File, D. M., Curigliano, G., & Carey, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100023 · Cited by 22
Chen, D. H., Tyebally, S. M., Mallouppas, M., Roylance, R. R., Spurrell, E. L., Raja, F. A., & Ghosh, A. K. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01446-x · Cited by 24
Personalized therapeutic strategies in HER2-driven gastric cancer
Ughetto, S., Migliore, C., Pietrantonio, F., Apicella, M., Petrelli, A., D’Errico, L., Durando, S., Moya‐Rull, D., Bellomo, S. E., Rizzolio, S., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01165-w · Cited by 22
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Bakhtiarvand, V. K., Akbari, K. R.-A., Jalali, S. A., Hojjat‐Farsangi, M., Jeddi‐Tehrani, M., Shokri, F., & Shabani, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109470 · Cited by 22
Margetuximab in HER2-positive metastatic breast cancer
Gradishar, W. J., O'Regan, R. M., Rimawi, M. F., Nordstrom, J. L., Rosales, M. K., & Rugo, H. S. (2023) · Future Oncology · doi:10.2217/fon-2022-1040 · Cited by 22
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
Yang, C., Brezden‐Masley, C., Joy, A. A., Sehdev, S. R., Modi, S., Simmons, C. E., & Henning, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231175440 · Cited by 24
Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue
Lorenzi, E., Simonelli, M., & Santoro, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.005 · Cited by 21
Elwy, F., Helwa, R., Leithy, A. A. E., Shehab El din, Z., Assem, M., & Hassan, N. H. A. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.1.57 · Cited by 21
Saraf, A., Grubb, C. S., Hwang, M. E., Tai, C.-H., Wu, C., Jani, A., Lapa, M. E., Andrews, J. I. S., Vanderkelen, S., Isaacson, S. R., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2549-y · Cited by 21
Joint modeling of progression‐free and overall survival and computation of correlation measures
Meller, M., Beyersmann, J., & Rufibach, K. (2019) · Statistics in Medicine · doi:10.1002/sim.8295 · Cited by 30
Inoue, K., Ninomiya, J., Saito, T., Okubo, K., Nakakuma, T., Yamada, H., Kimizuka, K., Higuchi, T., & for the SBCCSG-36 investigators (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00755-x · Cited by 21
Gogia, A., Deo, S., Sharma, D., Thulkar, S. P., Kumar, R., Malik, P. S., & Mathur, S. R. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00265 · Cited by 21
Steenbruggen, T. G., Bouwer, N. I., Smorenburg, C. H., Rier, H. N., Jager, A., Beelen, K. J., ten Tije, A. J., de Jong, P. C., Drooger, J. C., Holterhues, C., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05427-1 · Cited by 25
HER2-targeted multimodal imaging of anaplastic thyroid cancer.
Wei, W., Jiang, D., Rosenkrans, Z. T., Barnhart, T. E., Engle, J. W., Luo, Q., & Cai, W. (2019) · PubMed · Cited by 27
Current treatment options for HER2-positive breast cancer patients with brain metastases
Galanti, D., Inno, A., Vecchia, M. L., Borsellino, N., Incorvaia, L., Russo, A. D., & Gori, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103329 · Cited by 24
Sussell, J. A., Jhuti, G. S., Antao, V., Herrera-Restrepo, O., Wehler, E., & Bilir, S. P. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000816 · Cited by 21
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 25
Zengel, B., Kilic, M., Taşlı, F., Şimşek, C., Karataş, M., Özdemir, Ö., Çavdar, D. K., Durusoy, R., Baş, K., & Uslu, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-99726-7 · Cited by 21
Yin, Y., Yang, H., Liu, Z., Tan, J., Zhu, C., Chen, M., Zhou, R., Wang, L., & Qian, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s281765 · Cited by 21
Perez, E. A., Dang, C. T., Lee, C., Singh, J. C., Wang, K., Layton, J. B., Gilsenan, A., Hackshaw, M. D., & Cortés, J. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06469-0 · Cited by 20
Self-citationMaddox, A. L., Brehove, M. S., Eliato, K. R., Saftics, A., Romano, E., Press, M. F., Mortimer, J. E., Jones, V., Schmolze, D. D., Seewaldt, V. L., et al. (2022) · Cancers · doi:10.3390/cancers14112795 · Cited by 21
Nicolini, A., Ferrari, P., & Carpi, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102511 · Cited by 20
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
Kayıkçıoğlu, E., & Yüceer, R. O. (2023) · Medicine · doi:10.1097/md.0000000000032882 · Cited by 20
Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates
Kim, S., Kim, S., Kim, S., Kim, N., Lee, S., Yi, H., Lee, S., Sim, T., Kwon, Y., & Lee, H. S. (2023) · Advanced Science · doi:10.1002/advs.202306401 · Cited by 22
Self-citationTargeted therapies in gastric cancer treatment: where we are and where we are going
Tomasello, G., Ghidini, M., Liguigli, W., Ratti, M., Toppo, L., & Passalacqua, R. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0330-2 · Cited by 22
Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona, N., Gambardella, V., Huerta, M., Roselló, S., & Cervantes, A. M. R. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0525-x · Cited by 22
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035)
Tartari, F., Santoni, M., Pistelli, M., & Berardi, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.005 · Cited by 20
Leung, H. W. C., Chan, A. L. F., Muo, C., & Leung, J. H. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1386559 · Cited by 20
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series
Giannone, G., Milani, A., Ghisoni, E., Genta, S., Mittica, G., Montemurro, F., & Valabrega, G. (2018) · The Breast · doi:10.1016/j.breast.2018.01.006 · Cited by 20
Guérin, M., Gonçalvès, A., Toiron, Y., Baudelet, É., Pophillat, M., Granjeaud, S., Fourquet, P., Jacot, W., Tarpin, C., Sabatier, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26031 · Cited by 21
Woodward, N. E., Boer, R. H. D., Redfern, A. D., White, M. A., Young, J., Truman, M., & Beith, J. M. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.02.008 · Cited by 22
Lee, J., Franovic, A., Shiotsu, Y., Kim, S. T., Kim, K.-M., Banks, K. C., Raymond, V. M., & Lanman, R. B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00212 · Cited by 25
Self-citationMusolino, A., Boggiani, D., Pellegrino, B., Zanoni, D., Sikokis, A., Missale, G., Silini, E. M., Maglietta, G., Frassoldati, A., & Michiara, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102927 · Cited by 20
Russo, C. D., Cappoli, N., & Navarra, P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02895-z · Cited by 20
Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
Stüber, J. C., Richter, C. P., Bellón, J. S., Schwill, M., König, I., Schuler, B., Piehler, J., & Plückthun, A. (2021) · Communications Biology · doi:10.1038/s42003-021-02253-4 · Cited by 21
Novel applications of molecular imaging to guide breast cancer therapy
Edmonds, C. E., O’Brien, S. R., Mankoff, D. A., & Pantel, A. R. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00468-0 · Cited by 21
Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer
Sutherland, S., Miles, D., & Makris, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.019 · Cited by 20
Schuurman, J., & Parren, P. W. H. I. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.001 · Cited by 20
Limits to Precision Cancer Medicine.
Tannock, I. F., & Hickman, J. A. (2017) · PubMed · doi:10.1056/nejmc1613563 · Cited by 17
Mechanisms of resistance to antibody-drug conjugates in breast cancer
Çerçi, B., Saatci, Ö., Basik, M., & Şahin, Ö. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101353 · Cited by 26
Raphael, J., & Verma, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3342-2 · Cited by 19
Matikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
Chawla, A., Peeples, M., Li, N., Anhorn, R., Ryan, J., & Signorovitch, J. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2017.1423488 · Cited by 19
Tymon‐Rosario, J., Bonazzoli, E., Bellone, S., Manzano, A., Pelligra, S., Guglielmi, A., Gnutti, B., Nagarkatti, N., Zeybek, B., Manara, P., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.014 · Cited by 19
Kim, J., Nam, S. J., Lee, J. E., Yu, J., Chae, B. J., Lee, S. K., Ryu, J. M., Ahn, J. S., Im, Y., Kim, S. W., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.901 · Cited by 19
Self-citationPrisciandaro, M., Antista, M., Raimondi, A., Corti, F., Morano, F., Centonze, G., Sabella, G., Mangogna, A., Randon, G., Pagani, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.780716 · Cited by 22
From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
Sun, J., Li, X., Chen, P., & Gao, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s368138 · Cited by 20
Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance
Farooq, F., Amin, A., Wani, U. M., Lone, A., & Qadri, R. A. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31048 · Cited by 21
Allosteric crosstalk in modular proteins: Function fine-tuning and drug design
Abhishek, S., Deeksha, W., Nethravathi, K. R., Davari, M. D., & Rajakumara, E. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.013 · Cited by 21
Unveiling promising targets in gastric cancer therapy: A comprehensive review
Li, W., Wei, J., Cheng, M., & Liu, M. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200857 · Cited by 27
Updates in Treatment of HER2-positive Metastatic Breast Cancer
Avelino, A. R. M., Pulipati, S., Jamouss, K. T., & Bhardwaj, P. V. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01277-2 · Cited by 22
Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer
Hong, Y. C., He, J., Deng, D., Liu, Q., Zu, X., & Shen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06367-9 · Cited by 21
Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.
Woo, J., Cohen, S. A., & Grim, J. E. (2015) · Gastroenterology report · doi:10.1093/gastro/gov052 · Cited by 21
Hodeib, M., Serna-Gallegos, T. R., & Tewari, K. S. (2015) · Future Oncology · doi:10.2217/fon.15.266 · Cited by 20
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
Blum, J. L., Gonçalvès, A., Efrat, N., Debled, M., Conte, P., Richards, P. D., Richards, D., Lardelli, P., Nieto, A., Cullell-Young, M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3675-x · Cited by 19
Isbary, G., Staab, T. R., Amelung, V. E., Dintsios, C., Iking‐Konert, C., Nesurini, S. M., Walter, M., & Ruof, J. (2017) · Value in Health · doi:10.1016/j.jval.2017.09.010 · Cited by 19
Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
Gleeson, J. P., Keegan, N. M., & Morris, P. G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1410132 · Cited by 20
Racial disparity in breast cancer: can it be mattered for prognosis and therapy
Gupta, V. G., Haque, I., Chakraborty, J., Graff, S. L., Banerjee, S., & Banerjee, S. K. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0416-4 · Cited by 20
Tajmohammadi, I., Mohammadian, J., Sabzichi, M., Mahmuodi, S., Ramezani, M., Aghajani, M., & Ramezani, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28678 · Cited by 19
RetractedBattisti, N. M. L., Tong, D. K. H., Ring, A. E., & Smith, I. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05406-6 · Cited by 20
Selvaraj, J., Durai, U., Latha, S., Ayyamperumal, S., Wadhwani, A., & Prabha, T. (2020) · Current Drug Research Reviews · doi:10.2174/2589977512999200821170221 · Cited by 20
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
Iwase, T., Shrimanker, T. V., Rodríguez‐Bautista, R., Sahin, O., James, A., Wu, J., Shen, Y., & Ueno, N. T. (2021) · Cancers · doi:10.3390/cancers13112650 · Cited by 21
The Present and Future of Clinical Management in Metastatic Breast Cancer
Lin, P., & Laliotis, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195891 · Cited by 20
Treatment of HER2-Positive Metastatic Breast Cancer
Swain, S. M., Clark, E., & Baselga, J. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1503446 · Cited by 19
Self-citationPuccini, A., Viscardi, G., Ciani, O., Efficace, F., Piattelli, A., Beretta, G. D., Petruzzelli, D., Popoli, P., Lorenzo, F. D., Longo, F., et al. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000783 · Cited by 27
Dépistage du cancer du sein : en route vers le futur
Delaloge, S., Bachelot, T., Bidard, F., Espié, M., Brain, E. G. C., Bonnefoi, H. R., Gligorov, J., Dalenc, F., Bessard, A. C. H., Azria, D., et al. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.06.005 · Cited by 19
Self-citationKeegan, N. M., Furney, S. J., Walshe, J. M., Gullo, G., Kennedy, M., Smith, D., McCaffrey, J., Kelly, C. M., Egan, K., Kerr, J., et al. (2021) · Cancers · doi:10.3390/cancers13061225 · Cited by 18
Wang, X., Wang, L., Yu, Q., Liu, Z., Li, C., Wang, F., & Yu, Z. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211037812 · Cited by 18
Welslau, M., Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., Schütz, F., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9952 · Cited by 18
Li, Y., Chen, G.-L., Xiang, Z., Liu, Y., Li, X., Bi, J.-W., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114648 · Cited by 22
Li, R., Sant, S. A., Brown, E., Caramia, F., Nikolic, B., Clarke, K. A., Byrne, A., Gonzalez, L. E. L., Savas, P. S., Luen, S. J., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad072 · Cited by 18
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
Pegram, M. D., Pietras, R. J., Dang, C. T., Murthy, R. K., Bachelot, T., Janni, W., Sharma, P., Hamilton, E. P., & Saura, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187201 · Cited by 21
Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
Premji, S., & O'Sullivan, C. C. (2024) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234241234418 · Cited by 21
Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer
Chen, L., Xu, Y., Wang, Y., Ren, Y., Chen, Y., Zheng, C., Xie, T., Jia, Y., & Zhou, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118265 · Cited by 20
Malignant Pleural Effusion: A Multidisciplinary Approach
Pardessus, A., Rafecas, A., Porcel, J. M., Serra, P., Ferreiro, L., Botana‐Rial, M., Hernández, C. R., Brenes, J. M., Canales, L., Camacho, V., et al. (2024) · Open Respiratory Archives · doi:10.1016/j.opresp.2024.100349 · Cited by 25
Schmidt, C., & Storsberg, J. (2015) · Biomedicines · doi:10.3390/biomedicines3030203 · Cited by 19
Wang, Z., Ma, Y., Wang, H., Wang, F., Xu, T., & Gu, Y. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201905480 · Cited by 18
Gao, M., Fu, C., Li, S., Chen, F., Yang, Y., Wang, C., Qin, J., Liu, S., Ranran, Z., Wang, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4481 · Cited by 18
Normann, L. S., Haugen, M. H., Aure, M. R. R., Kristensen, V. N., Mælandsmo, G. M., & Sahlberg, K. K. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s338404 · Cited by 19
Yamashita, T., Masuda, N., Saji, S., Araki, K., Ito, Y., Takano, T., Takahashi, M., Tsurutani, J., Koizumi, K., Kitada, M., et al. (2020) · Trials · doi:10.1186/s13063-020-04341-y · Cited by 18
Biopsy of breast cancer metastases: patient characteristics and survival
Shachar, S. S., Mashiach, T., Fried, G., Drumea, K. C., Shafran, N., Muss, H. B., & Bar‐Sela, G. (2017) · BMC Cancer · doi:10.1186/s12885-016-3014-6 · Cited by 18
Immunotherapy for the treatment of breast cancer
Ayala, M. A. M., Gottardo, M. F., Asad, A. S., Zuccato, C. F., Candia, A. J. N., Seilicovich, A., & Candolfi, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1324566 · Cited by 22
Wang, B., Deng, R., Hennig, S., Črnjević, T. B., Kaewphluk, M., Kågedal, M., Quartino, A. L., Girish, S., Li, C., & Kirschbrown, W. P. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04296-0 · Cited by 20
Cardiac morbidity & mortality in patients with breast cancer
Dhir, A. A., & Sawant, S. P. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_879_20 · Cited by 17
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
Essâdi, I., Benbrahim, Z., Kaakoua, M., Reverdy, T., Corbaux, P., & Freyer, G. (2023) · Cancers · doi:10.3390/cancers15061738 · Cited by 18
Fu, P., Shen, C., Yang, S., Lee, C., Chen, H., Lai, E. C., & Chung, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-35308-z · Cited by 17
Bhardwaj, P. V., & Abdou, Y. G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad233 · Cited by 19
Yoon, S. M., & Bazan, J. G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01529-2 · Cited by 19
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Deiana, C., Agostini, M., Brandi, G., & Giovannetti, E. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357802 · Cited by 19
Bendell, J. C., Zakari, A., Lang, E., Waterhouse, D. M., Flora, D. B., Alguire, K. B., McCleod, M., Peacock, N. W., Ruehlman, P., Lane, C. M., et al. (2016) · Cancer Investigation · doi:10.3109/07357907.2016.1174257 · Cited by 17
Yuan, P., & Gao, S. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.01.004 · Cited by 20
Tóth, G., Szöllõsi, J., & Vereb, G. (2017) · Cytometry Part A · doi:10.1002/cyto.a.23247 · Cited by 17
Miles, D. K., Im, Y., Fung, A., Yoo, B., Knott, A., Heeson, S., Beattie, M. S., & Swain, S. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx406 · Cited by 18
Self-citation
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.